Establishment Labs Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 45% revenue growth, gross margin expansion to 70.7%, and strong U.S. momentum, driven by Motiva adoption and minimally invasive platform launches. Guidance was raised for 2026, with continued profitability and cash flow positive expected in H2.
-
2025 saw exceptional U.S. growth for Motiva, driven by innovative marketing, premium pricing, and strong account expansion. 2026 guidance projects continued momentum, new product launches, and margin expansion, with international and reconstruction segments poised for further growth.
-
Strong 2025 results with 27% global growth and rapid U.S. market share gains set the stage for at least 25% annual growth in 2026–2027. Key drivers include innovative minimally invasive products, expanded sales force, and robust marketing, with international markets and new indications poised to further accelerate growth.
Fiscal Year 2025
-
Q4 2025 saw revenue surge 45% year-over-year, with strong US and international growth, gross margins above 70%, and a significant turnaround to positive adjusted EBITDA. 2026 guidance projects 25%+ revenue growth, continued margin expansion, and cash flow positivity.
-
Strong U.S. entry and innovation are driving rapid growth, with market share expected to reach 20% by year-end and minimally invasive products expanding the market. International focus on direct markets and new pipeline products like JEM and Recon Indication support long-term growth.
-
Q3 2025 delivered 34% revenue growth, record 70.1% gross margin, and the first positive EBITDA. U.S. and international direct markets showed strong momentum, with 2025 revenue guidance raised above $210M and cash flow positive targeted for 2026.
-
Second quarter revenue grew 16% year-over-year to $51.3 million, led by strong U.S. performance and robust European direct market growth. Adjusted EBITDA loss narrowed, and 2025 revenue guidance was raised to $208–$212 million, with positive EBITDA expected later this year.
-
Strong U.S. growth, a robust innovation pipeline, and premium pricing are driving rapid adoption and market expansion, especially with minimally invasive platforms and new indications. Surgeons and patients are fueling a shift toward safer, natural results, while the competitive landscape remains favorable.
-
Management highlighted a differentiated product portfolio, robust U.S. expansion, and strong financial guidance for 2025. New launches like Mia and Preservé are expanding markets and margins, while disciplined operations support EBITDA profitability by year-end.
-
Q1 2025 revenue grew 11% year-over-year to $41.4 million, with U.S. sales and Motiva implant adoption exceeding expectations. Guidance for 2025 revenue remains $205–$210 million, with improving gross margins and a path to profitability by 2026.
-
Leadership transition is underway with the founder focusing on innovation and advocacy. The U.S. Motiva launch is driving rapid adoption, premium product mix, and strong financial outlook, while new products and minimally invasive platforms are set to expand growth internationally and in the U.S.
-
Management transition brings renewed focus on operational discipline and profitability, with no major strategic shifts. Strong Q4 results, robust U.S. launch, and expanding innovation pipeline support positive 2025 guidance and margin improvement.
-
Leadership transitions formalize a collaborative structure, with a new president focusing on operational discipline and profitability. Strong 2025 guidance, innovative minimally invasive platforms, and robust U.S. and international growth position the company for sustained expansion and improved margins.
Fiscal Year 2024
-
Q4 revenue grew 41% year-over-year to $44.5M, with strong U.S. launch momentum and improved margins. 2025 guidance targets $205–$210M revenue, EBITDA positive in H2, and cash flow positive in 2026, supported by new product launches and global expansion.
-
Strong U.S. launch with rapid account onboarding and high surgeon interest is driving growth, supported by robust manufacturing and a differentiated product portfolio. Internationally, growth continues despite some regional softness, while new products like Mia are expanding the market.
-
Proprietary technologies and minimally invasive solutions are driving rapid market expansion, especially in the U.S. and China. Financial discipline and a strong cash position support a path to profitability by 2026, with new product launches and clinical milestones expected in 2025.
-
Strong Q3 results and operational improvements set the stage for a pivotal 2025, with FDA approval enabling a robust U.S. launch and global expansion. Innovation in minimally invasive and gluteal aesthetics, along with a focus on profitability, positions the company for sustained growth.
-
Q3 revenue grew 4.5% to $40.2M, with strong U.S. Motiva launch and improved cost controls. Pro forma cash reached $114M after new financing, and 2025 is expected to bring EBITDA positivity and over $35M in U.S. revenue.
-
Q2 revenue grew 18.7% sequentially to $44.1M, with strong recovery in EMEA and APAC but ongoing weakness in Brazil. FDA approval for Motiva Implants is expected soon, supporting U.S. launch preparations and global expansion. Gross margin improved to 65.6% year-over-year.
-
The conference highlighted a strong innovation pipeline in breast aesthetics and reconstruction, with global expansion into China and the U.S., regulatory milestones, and a path to profitability by next year. Next-generation products and minimally invasive platforms are set to drive further growth.
-
Management highlighted strong global expansion, regulatory progress in the U.S., and the successful rollout of innovative products like Mia and Flora. Financial guidance points to EBITDA positivity by year-end (ex-U.S.) and rising gross margins as premium products gain traction.